

**M Abbasi MD**

Associate prof, TUMS

24 Oct, 2021

# Role of PET Scan in breast cancer metastasis workup ?

- ~~Screening~~
- ~~Diagnosis~~
- Staging
- Restaging
- Response to treatment
- Recurrence
- Surveillance





National Comprehensive  
Cancer Network<sup>®</sup>

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>)**











# **Breast Cancer**

**NCCN Evidence Blocks<sup>™</sup>**

Version 8.2021 — September 13, 2021

# Role of PET Scan •

- Can be performed at the time of Diagnostic CT ( most helpful at suspicious lesion and equivocal findings & unsuspected nodal metastases)
- Before systemic therapy; recurrence; surveillance



[doi.org/10.3892/etm.2012.659](https://doi.org/10.3892/etm.2012.659)

# Journal Pre-proof

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer<sup>†</sup>

A. Gennari, F. André, C.H. Barrios, J. Cortés, E. de Azambuja, A. DeMichele, R. Dent, D. Fenlon, J. Gligorov, S.A. Hurvitz, S.-A. Im, D. Krug, W.G. Kunz, S. Loi, F. Penault-Lorca, J. Ricke, M. Robson, H.S. Rugo, C. Saura, P. Schmid, C.F. Singer, T. Spanic, S.M. Tolaney, N.C. Turner, G. Curigliano, S. Loibl, S. Paluch-Shimon, N. Harbeck, on behalf of the ESMO Guidelines Committee

PII: S0923-7534(21)04498-7

DOI: <https://doi.org/10.1016/j.annonc.2021.09.019>

Reference: ANNONC 766

To appear in: *Annals of Oncology*










Received Date: 28 September 2021




# STAGING AND RISK ASSESSMENT

- May be used instead of CT and bone scans
- May provide earlier guidance in monitoring bone-only/predominant metastases, but prospective trials are needed to study the impact on treatment decisions and OS





[FDG-PET/CT is accurate in diagnosing breast cancer recurrence – Atlas of Science](#)



[doi.org/10.1016/j.juro.2010.12.050](https://doi.org/10.1016/j.juro.2010.12.050)

- **Stage 1: recommends against** (strong recommendation, very low certainty of the evidence)
- **Stage 2: against**(conditional recommendation, very low certainty of the evidence)
- **Stage 3: suggests using rather than conventional W/U** (conditional recommendation, low certainty of the evidence)

